Roche has secured its third antibody-drug conjugate pact of the year, this time agreeing to hand $36 million in upfront payments to Oxford BioTherapeutics. The agreement will also see U.K.-based Oxford in line for milestone payments that could exceed $1 billion, along with a slice of the royalties from potential sales. The “multiple” oncology targets for the collaboration will be identified by Oxford’s OGAP-Verify discovery platform, Source: Fierce Biotech 19/3/2025